Immunic Inc

Immunic’s new CEO, Erik Lundgren, aligns with the upcoming Phase‑2 CALLIPER data on Vidofludimus Calcium, promising a boost in MS therapy prospects and investor confidence.

Imunic’s board gains Jon Congleton, a 4‑decade biopharma veteran, to accelerate late‑stage oral immunology therapies and boost investor confidence.

Immunic Inc. continues to focus on developing oral immunology therapies for chronic diseases, but must navigate the evolving biotech landscape, including leadership changes at companies like Hansa Biopharma.

Immunic Inc.’s stock experienced significant volatility after mixed trial results for its multiple sclerosis drug, but promising Phase 2 trial data also highlighted the drug’s potential therapeutic benefits.

Immunic Inc.’s stock has experienced mixed reactions following recent multiple sclerosis trial updates, with promising Phase 2 results offset by disappointing mid-stage data.